Lenalidomid Pharmascience (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This triggers the ubiquitination and degradation of transcription factors Ikaros and Aiolos, leading to reduced tumor‑cell proliferation, enhanced immune‑mediated cytotoxicity, and inhibition of new blood‑vessel formation that supports cancer growth.

The dose of Lenalidomid Pharmascience is individualized by the prescribing physician based on the specific indication, disease stage, renal function, and patient tolerance. The prescriber determines the appropriate strength, frequency, and duration of therapy according to current clinical guidelines and patient needs.

Lenalidomid Pharmascience is classified as Pregnancy Category X because it is known to cause fetal harm and is contraindicated during pregnancy. Women of child‑bearing potential must use effective contraception during treatment and for a defined period after the last dose. The product is also not recommended for breastfeeding mothers as it may be excreted in milk.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

The primary alternative to lenalidomide is thalidomide, another immunomodulatory drug. Lenalidomide generally offers a more favorable safety profile, with lower rates of peripheral neuropathy, and it provides stronger anti‑angiogenic and immune‑stimulating effects. Both agents share teratogenic risk, but lenalidomide is often preferred for patients who cannot tolerate thalidomide’s neurotoxic side effects.

Lenalidomid Pharmascience tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or other humid environments.

The medication is taken orally, usually with a glass of water. It may be taken with or without food, but patients should follow the prescriber’s instructions regarding timing relative to meals. Swallow the tablet whole; do not crush, split, or chew unless specifically directed by a healthcare professional.

Serious risks include venous thromboembolism (blood clots), secondary primary malignancies, severe skin reactions such as Stevens‑Johnson syndrome, hepatic failure, tumor lysis syndrome, and interstitial lung disease. Patients should promptly report symptoms like unexplained swelling, severe rash, jaundice, sudden shortness of breath, or persistent fever to their healthcare provider.

Lenalidomid Pharmascience should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or any excipients, patients with severe renal impairment without dose adjustment, and those who cannot adhere to the required contraception program. It is also contraindicated in patients with active, uncontrolled infections where immune suppression could worsen the condition.